Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01952223 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

Study acronym: PEACE2
StatusActive, Not Recruiting
PhasePhase 3
SponsorUNICANCER
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 30, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. 3 versions Re-verified since Oct 28, 2022, no change to tracked fieldsv11-v13
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 1048 to confirmed 761 · Completion date: Dec 2032 to Jul 2041 · Site details revisedv10 Show 3 more changesShow less
    • Enrollment target: estimated 1048 to confirmed 761
    • Completion date: Dec 2032 to Jul 2041
    • Site details revised
  3. Trial status: Suspended to Recruiting Study description revised · Site details revisedv9 Show 2 more changesShow less
    • Study description revised
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Recruiting to Suspended Sponsor's reason: Temporary suspension since March 20 due to COVID-19 pandemic Site details revised · Eligibility criteria shortened, about 3 words · Study description expanded, about 5 wordsv8 Show 3 more changesShow less
    • Site details revised
    • Eligibility criteria shortened, about 3 words
    • Study description expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  5. Collaborators expanded, about 1 wordv7 See this version in full on ClinicalTrials.gov ↗
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Sep 2019 to Dec 2025 Start date: Sep 2013 to Dec 2013 · Completion date: Sep 2026 to Dec 2032v6 Show 2 more changesShow less
    • Start date: Sep 2013 to Dec 2013
    • Completion date: Sep 2026 to Dec 2032
  2. Re-verified, no change to tracked fieldsv5
  3. Eligibility criteria expanded, about 9 wordsv4 See this version in full on ClinicalTrials.gov ↗
  4. Eligibility criteria revised Site contact updatedv3 Show 1 more changeShow less
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Active, Not Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
UNICANCER
98 trials monitored
See 7 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with high-risk localized prostate cancer (with a stringent selection of patients with at least 2 high-risk features), in a 2 by 2 factorial trial.
Trial Details
NCT Number NCT01952223
Lead Sponsor UNICANCER
Collaborators: Sanofi
Conditions Adenocarcinoma of Prostate, Progression of Prostate Cancer
Enrollment 761 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov